Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Consultation To Help Determine Whether EU SPC Framework Fit For Purpose

The European Commission has launched a consultation on proposals to “recalibrate” supplementary protection certificates and patent research exemptions.

Europe Biosimilars

Row Erupts Over “Third Way” For Biosimilar Approvals In Colombia

Colombia’s health ministry has accused the R&D-based pharmaceutical industry association of prioritizing monopolies over patients after its attempts to suspend legislation that promises a faster route to market for biosimilars.

Colombia BioPharmaceutical

Australia Moves Forward With Biovigilance Guidelines

Australia’s regulator has responded to consultation submissions and is moving forward with plans to issue guidance on biovigilance.

Australia Biologics

New HTA Methodology Could Solve Value Conundrum

A new methodology for evaluating the benefits of new medicines aims to make funding decisions more transparent and structured. It could also offer an alternative to the way health technology appraisals reflect value.

Cost Effectiveness Health Technology Assessment

Brazil Needs Better Orphan Drug Policies, Says Alexion

Strengthening Brazil’s policy on orphan drugs would help stem the number of court cases brought by patients to access medicines, says Alexion.

Market Access Pricing Debate

Janssen Deal Could Signal Clinical Trial Revival In Argentina

Janssen’s commitment to invest more in clinical research in Argentina could be a sign that new regulations are bringing back clinical research to the country.

Clinical Trials Argentina
See All
Advertisement
UsernamePublicRestriction

Register